Merck & Co., Inc. (MRK) Cash Flow Statement

In 2026Q2, operating cash flow of $5.4B against a net loss of $1.3B implies a conversion ratio of -4.02, indicating that cash generation remains robust despite accounting losses. The prior quarter's OCF/NI of -0.92 similarly reflects non-cash charges, likely from R&D impairments or acquisition costs, which may not recur. Investors should monitor whether these charges are truly one-time or signal ongoing margin pressure.

The FCF margin has ranged from 7.5% to 51.1% over the past ten quarters, with the most recent quarter at 27.0% despite a net loss. This volatility appears tied to working capital changes and the R&D spike in 2026Q1, which may indicate that cash flow is more stable than earnings suggest. However, the 2026Q1 FCF of $2.9B was still positive, suggesting that the company's cash-generating core remains intact.

CapEx/Revenue has stayed within a narrow band of 4.7% to 8.5%, with the higher figure in 2025Q1 likely reflecting Gardasil capacity expansion. This suggests that Merck is investing for growth, particularly in manufacturing, rather than merely maintaining existing assets. The consistency of capex relative to revenue implies that capital intensity is not a major swing factor, but the forward-looking bet on Gardasil capacity may not pay off if demand disappoints.

The negative working capital changes in 2025Q1 and 2026Q1 suggest that Merck is using cash to build inventory or extend receivables, possibly ahead of product launches. Conversely, positive changes in 2024Q3 and 2026Q2 indicate collections or inventory drawdowns. These swings appear to be a primary driver of the gap between net income and operating cash flow, and investors should expect continued volatility.

Dividend payments have been remarkably stable at around $2.0B per quarter, indicating a strong commitment to shareholder returns. Buybacks have been more variable, with a notable $2.5B repurchase in 2025Q3, but they were absent in 2025Q3 (actually a positive $2.5B, suggesting issuance). The company also made significant acquisition outflows, including $10.0B in 2025Q4 and $8.8B in 2026Q1, which may strain liquidity if not offset by operating cash flow.

The cumulative gap of $17.3B suggests that earnings are understated relative to cash generation, likely due to non-cash charges such as amortization and impairments. This divergence may indicate that Merck's underlying cash profitability is stronger than GAAP earnings suggest, but it also raises questions about the sustainability of these charges. Investors should monitor whether this gap narrows as one-time items fade.